Navigation Links
A gene that protects against colorectal cancers
Date:12/14/2011

The research team at Lyon has developed an animal model carrying a mutation of the DCC gene. Mice carrying the mutation develop tumours, because this gene can no longer induce the death of the cancer cells. This discovery could lead to the development of a new targeted cancer treatment that aims to reactivate the dying of cancer cells.

The results of this study have been published as a Letter in the 11th December 2011 issue of the journal Nature.

The team led by Patrick Mehlen, Director of the DEVweCAN 'Laboratory of Excellence' at the Lyon Cancer Research Centre (CNRS/Inserm/Centre Lon Brard/Universit Claude Bernard 1), studies the cell death process (apoptosis) and, in particular, the mechanism that makes the cells understand that they should initiate a self-destruction process when they become abnormal. Patrick Mehlen's team suggested that this mechanism could operate via sentinels located on the surface of cells, which examine their environment. The scientists named these sentinels 'dependence receptors'.

The research team focused on this concept of 'dependence receptors'. When a cell receptor is associated with its ligand, the classic message indicates 'all is well', and leads to cell survival. On the other hand, when the receptor is deprived of its ligand, it can send a message leading to cell death. This mechanism is also called 'apoptosis.' When this is applied to cancer research, the absence of ligands could cause the death of cancer cells that proliferate in an anarchic manner.

In this study, Patrick Mehlen's team shows that the DCC gene (Deleted Colorectal Cancer), which codes for a 'dependence receptor', protects the organism from the onset of cancer by causing the death of cells that become cancerous. The researchers used a mouse model where the DCC gene has been genetically modified. The mutation of this dependence receptor prevents the induction of apoptosis. When the DCC gene is eliminated by mutation, the mouse spontaneously develops colon cancer.

'The organism is naturally protected from the development of cancers thanks to the presence of this tumour-suppressing gene. Unfortunately, certain cancer cells escape from this control by blocking this 'dependence receptor' mechanism. That is how we know that the DCC gene is extinguished in most human cancers,' explains Patrick Mehlen.

In the near future, this research work could lead to a new targeted treatment that aims to reactivate the death of the cancer cells to destroy breast cancer, lung cancer, etc. 'Our group has developed several candidate drugs that reactivate the cell death induced by the DCC receptor in animal models, and we hope to be able to carry out human clinical testing of these candidate drugs in three years' time,' concludes Patrick Mehlen.


'/>"/>

Contact: Inserm Presse
presse@inserm.fr
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert

Related medicine news :

1. Happiness Protects Your Heart
2. New Insurance Membership Program Protects Washington State Families Against High Cost of Emergency Medical Transports
3. HIV drug that protects a fetus should be avoided for one year after childbirth, researchers say
4. Breastfeeding protects children against peptic ulcer bacterium
5. Bishops Encourage Vigilance that Health Care Legislation Protects Conscience, Does Not Fund Abortion
6. EarPeace Protects Hearing for Thousands at South by Southwest
7. A stress-response system in the ear protects against hearing loss
8. Study Challenges Notion That Moderate Drinking Protects the Heart
9. NIH-funded scientists find 2009 H1N1 pandemic influenza vaccine protects mice from 1918 flu virus
10. New Study Finds HPV Vaccine Protects Against Genital Warts
11. Widely used arthritis pill protects against skin cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... ... much-anticipated fall event , Look Awesome This Autumn with CoolSculpting®. Scheduled for ... pricing and refreshments. , Mirror Mirror Beauty Boutique is Houston’s largest ...
(Date:9/20/2017)... ... 2017 , ... Compliancy Group is proud to announce that ... helped another long-time client pass their Department of Health and Human Services (HHS) ... Thanks to the help of the Compliancy Group's Audit Response Program™, not a ...
(Date:9/20/2017)... ... ... Five consumer packaged goods (CPG) products were selected by the SupplySide editorial ... Plus was named to the short list in the Specialty Supplements category. , ... at SupplySide Central on Sept. 27 and 28 at Mandalay Bay Resort in Las ...
(Date:9/20/2017)... ... September 20, 2017 , ... Recognising that ... program from Leany Greeny delivers positive results in just three weeks. Setting the ... kickstart the metabolism. Fitting seamlessly into hectic work and family schedules, participants can ...
(Date:9/20/2017)... ... ... Houston, Texas, investment firm CORDA Investment Management, LLC, believes in giving back. That’s ... and rolled up their sleeves to help with relief efforts. The team picked up ... of rebuilding. , CORDA founder Bonner C. Barnes notes that investment management firms have ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... NEWTOWN, Pa. , Sept. 5, 2017  Xyntek Inc. has announced another ... opened a new Midwest office to meet the growing demands of customer engagements ... Xyntek's new Midwest office is located at ... ... demands of customer engagements regionally. ...
(Date:9/5/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... its meeting with the U.S. Food and Drug Administration ... At the meeting, ... for submission of ORMD-0801, would be a Biologics License ...
(Date:9/1/2017)... 2017  Bayer will present the latest research from across ... Oncology (ESMO) 2017 Congress, September 8-12 in Madrid, ... and clinical data on Bayer,s marketed portfolio and late-stage compounds ... "We value the opportunity ... research at ESMO," said Carsten Brunn , Head of ...
Breaking Medicine Technology: